AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Merck Steady -- After The Fall
The drug making giant's stock stabilized somewhat early Friday, a day after shares plummeted 28% when Merck pulled its blockbuster arthritis drug, Vioxx, from the global market because new data from a clinical trial found an increased risk of heart attack and stroke.
New Trial Requested Of Allergan
U.S. regulators won't approve Allergan's experimental treatment for the skin disorder psoriasis based on the data submitted. The Food and Drug Administration wants the firm to conduct a new clinical trial to prove the treatment is not inferior to other treatments for severe psoriasis.
Feds Ease Manufacturing Rules
Drug makers won't need regulatory approval for every change in their manufacturing processes under new guidelines designed to prevent supply ...